Novo Nordisk Foundation Center for Basic Metabolic Research

Novo Nordisk Foundation Center for Basic Metabolic Research
Name	Novo Nordisk Foundation Center for Basic Metabolic Research
Native name	Center for Basic Metabolic Research
Established	2010
Type	Research institute
Location	Copenhagen, Denmark
Affiliation	University of Copenhagen

Contents

Novo Nordisk Foundation Center for Basic Metabolic Research

The Novo Nordisk Foundation Center for Basic Metabolic Research is a translational research institute at the University of Copenhagen focused on metabolic science, integrating work across cell biology, physiology, genetics, and systems biology. Founded with philanthropic support from the Novo Nordisk Foundation, the Center bridges academic research with biomedical institutions, clinical partners, and industry including Novo Nordisk A/S, University of Oxford, Harvard University, and Karolinska Institutet to address diseases such as type 2 diabetes, obesity, and non-alcoholic fatty liver disease. It hosts international researchers from institutions like Massachusetts Institute of Technology, Stanford University, Max Planck Society, and Imperial College London to advance methods in metabolomics, genomics, and single-cell analysis.

History

The Center was established in 2010 following a major donation from the Novo Nordisk Foundation to the University of Copenhagen, joining earlier Danish research efforts at Copenhagen University Hospital, Rigshospitalet, and the Faculty of Health and Medical Sciences. Its founding aligned with initiatives by funders such as the European Research Council, Wellcome Trust, and Bill & Melinda Gates Foundation to concentrate metabolic research in Northern Europe. Early leadership recruited investigators from University of Cambridge, ETH Zurich, University of California, San Francisco, and Yale University, and partnered with networks including the Danish National Research Foundation and the Nordic EMBL Partnership. Over successive funding cycles the Center expanded facilities modeled after institutes like the Broad Institute and the Sanger Institute and integrated consortia with Genomics England, International Diabetes Federation, and European Molecular Biology Laboratory.

The Center’s mission emphasizes basic and translational studies of human metabolism, linking molecular mechanisms to clinical phenotypes observed by groups at Mayo Clinic, Cleveland Clinic, Karolinska University Hospital, and Johns Hopkins Hospital. Research focus areas include adipose biology informed by work from Cell Metabolism groups, pancreatic islet physiology comparable to labs at University of British Columbia, liver metabolism paralleling studies at Mount Sinai Health System, mitochondrial dynamics echoing Max Delbrück Center approaches, and circadian regulation influenced by collaborations with Salk Institute researchers. The Center applies technologies developed at Cold Spring Harbor Laboratory, European Bioinformatics Institute, National Institutes of Health, and Wellcome Sanger Institute to study genetic contributors to metabolic syndrome and to develop biomarkers used by clinical trials run by AstraZeneca, Novo Nordisk A/S, and Roche.

Organizational structure connects to the University of Copenhagen faculties and links administrative oversight with grant partners such as the Danish Health Authority, Novo Nordisk Foundation, and international funders like Horizon Europe and National Science Foundation. Leadership has included principal investigators recruited internationally from Harvard Medical School, University of California, Berkeley, University of Toronto, and KU Leuven, and governance boards with representatives from Novo Holdings, European Commission, Danish Ministry of Higher Education and Science, and academic councilors from Princeton University and ETH Zurich. Scientific advisory committees have featured members from Rockefeller University, Columbia University, UCSF, University of Pennsylvania, and University of Chicago.

Physical facilities echoing major centers such as the Francis Crick Institute and Weizmann Institute of Science include metabolomics platforms, imaging cores, and high-throughput genomics modeled after Broad Institute pipelines, with equipment supplied by companies tied to Thermo Fisher Scientific, Illumina, and Bruker. The Center collaborates with clinical partners at Bispebjerg Hospital, Herlev Hospital, Sahlgrenska University Hospital, and international centers including Karolinska Universitetssjukhuset and Charité – Universitätsmedizin Berlin for patient cohorts, and with consortia such as UK Biobank, INTERVAL Study, EPIC Study, 1000 Genomes Project, and ENCODE Project for data integration. Training programs are run jointly with universities including University of Copenhagen, Technical University of Denmark, University of Helsinki, University of Oslo, and Lund University.

Major programs encompass metabolomics led by investigators who have partnered with Metabolon, large-scale genomics aligned with GIANT Consortium, and single-cell atlasing comparable to Human Cell Atlas efforts. Achievements include mapping adipose tissue heterogeneity in collaboration with groups from Mount Sinai, identifying genetic loci related to insulin resistance paralleling findings from DIAGRAM Consortium, and developing mass-spectrometry workflows influenced by Stanford Medicine and European Molecular Biology Laboratory standards. The Center contributed to multi-cohort meta-analyses with partners such as CHARGE Consortium, International Mouse Phenotyping Consortium, ENCODE Project, and published work alongside authors from Nature Medicine, Cell, Science, and The Lancet Diabetes & Endocrinology that informed clinical guidelines at World Health Organization and European Association for the Study of Diabetes meetings.

Primary funding sources include the Novo Nordisk Foundation endowment and competitive grants from bodies such as the European Research Council, Horizon Europe, National Institutes of Health, and philanthropic funders like the Wellcome Trust and Knights of Columbus Charities. Governance incorporates university oversight from the University of Copenhagen Board and advisory input from external institutions such as Harvard University, Max Planck Society, and Karolinska Institutet, with partnerships involving industry stakeholders including Novo Nordisk A/S, AstraZeneca, Novo Holdings A/S, and collaborative agreements with networks like NordForsk and European Molecular Biology Laboratory.